ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
Everything Tesamorelin
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="BigTex" data-source="post: 222199" data-attributes="member: 43589"><p>Here is a lot of research on tesamorelin:</p><p></p><p>Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PLoS One. 2015 Oct 12;10(10):e0140358. doi: 10.1371/journal.pone.0140358. PMID:</p><p></p><p>Julian Falutz, M.D., Soraya Allas, M.D., Ph.D., Koenraad Blot, M.D., Diane Potvin, M.Sc., Donald Kotler, M.D., Michael Somero, M.D., Daniel Berger, M.D., Stephen Brown, M.D., Gary Richmond, M.D., Jeffrey Fessel, M.D., Ralph Turner, Ph.D., M.P.H., and Steven Grinspoon, M.D. Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. December 6, 2007</p><p>N Engl J Med 2007; 357:2359-2370. DOI: 10.1056/NEJMoa072375</p><p></p><p>Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10. PMID: 22495074; PMCID: PMC3348954.</p><p></p><p>Baker, L. D., Barsness, S. M., Borson, S., Merriam, G. R., Friedman, S. D., Craft, S., & Vitiello, M. V. (2012). Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of neurology, 69(11), 1420–1429. <a href="https://doi.org/10.1001/archneurol.2012.1970" target="_blank">Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults: Results of a Controlled Trial</a></p><p></p><p>Adrian, S., Scherzinger, A., Sanyal, A. et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging 8, 154–159 (2019). <a href="https://doi.org/10.14283/jfa.2018.45" target="_blank">The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV - The Journal of Frailty & Aging</a></p><p></p><p>Dhillon, S. Tesamorelin. Drugs 71, 1071–1091 (2011). <a href="https://doi.org/10.2165/11202240-000000000-00000" target="_blank">https://doi.org/10.2165/11202240-000000000-00000</a></p><p></p><p>Clinical Review Report: Tesamorelin (Egrifta) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. Executive Summary. Available from: <a href="https://www.ncbi.nlm.nih.gov/books/NBK539124/" target="_blank">Executive Summary - Clinical Review Report: Tesamorelin (Egrifta) - NCBI Bookshelf</a></p><p></p><p>Friedman SD, Baker LD, Borson S, et al. Growth Hormone–Releasing Hormone Effects on Brain γ-Aminobutyric Acid Levels in Mild Cognitive Impairment and Healthy Aging. JAMA Neurol. 2013;70(7):883–890. doi:10.1001/jamaneurol.2013.1425</p><p></p><p>Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011 May 28;71(8):1071-91. doi: 10.2165/11202240-000000000-00000. PMID: 21668043.</p><p></p><p>Patel A, Gandhi H, Upaganlawar A. Tesamorelin: A hope for ART-induced lipodystrophy. J Pharm Bioallied Sci. 2011;3(2):319-320. doi:10.4103/0975-7406.80763</p><p></p><p>Clinical Review Report: Tesamorelin (Egrifta) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. Executive Summary. Available from: <a href="https://www.ncbi.nlm.nih.gov/books/NBK539124/" target="_blank">Executive Summary - Clinical Review Report: Tesamorelin (Egrifta) - NCBI Bookshelf</a></p><p></p><p>Sami H. Tuffaha, Prateush Singh, Joshua D. Budihardjo, Kenneth R. Means, James P. Higgins, Jaimie T. Shores, Roberto Salvatori, Ahmet Höke, W.P. Andrew Lee & Gerald Brandacher (2016) Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury, Expert Opinion on Therapeutic Targets, 20:10, 1259-1265, DOI: 10.1080/14728222.2016.1188079</p></blockquote><p></p>
[QUOTE="BigTex, post: 222199, member: 43589"] Here is a lot of research on tesamorelin: Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PLoS One. 2015 Oct 12;10(10):e0140358. doi: 10.1371/journal.pone.0140358. PMID: Julian Falutz, M.D., Soraya Allas, M.D., Ph.D., Koenraad Blot, M.D., Diane Potvin, M.Sc., Donald Kotler, M.D., Michael Somero, M.D., Daniel Berger, M.D., Stephen Brown, M.D., Gary Richmond, M.D., Jeffrey Fessel, M.D., Ralph Turner, Ph.D., M.P.H., and Steven Grinspoon, M.D. Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. December 6, 2007 N Engl J Med 2007; 357:2359-2370. DOI: 10.1056/NEJMoa072375 Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10. PMID: 22495074; PMCID: PMC3348954. Baker, L. D., Barsness, S. M., Borson, S., Merriam, G. R., Friedman, S. D., Craft, S., & Vitiello, M. V. (2012). Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of neurology, 69(11), 1420–1429. [URL="https://doi.org/10.1001/archneurol.2012.1970"]Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults: Results of a Controlled Trial[/URL] Adrian, S., Scherzinger, A., Sanyal, A. et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging 8, 154–159 (2019). [URL="https://doi.org/10.14283/jfa.2018.45"]The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV - The Journal of Frailty & Aging[/URL] Dhillon, S. Tesamorelin. Drugs 71, 1071–1091 (2011). [URL]https://doi.org/10.2165/11202240-000000000-00000[/URL] Clinical Review Report: Tesamorelin (Egrifta) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. Executive Summary. Available from: [URL="https://www.ncbi.nlm.nih.gov/books/NBK539124/"]Executive Summary - Clinical Review Report: Tesamorelin (Egrifta) - NCBI Bookshelf[/URL] Friedman SD, Baker LD, Borson S, et al. Growth Hormone–Releasing Hormone Effects on Brain γ-Aminobutyric Acid Levels in Mild Cognitive Impairment and Healthy Aging. JAMA Neurol. 2013;70(7):883–890. doi:10.1001/jamaneurol.2013.1425 Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011 May 28;71(8):1071-91. doi: 10.2165/11202240-000000000-00000. PMID: 21668043. Patel A, Gandhi H, Upaganlawar A. Tesamorelin: A hope for ART-induced lipodystrophy. J Pharm Bioallied Sci. 2011;3(2):319-320. doi:10.4103/0975-7406.80763 Clinical Review Report: Tesamorelin (Egrifta) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. Executive Summary. Available from: [URL="https://www.ncbi.nlm.nih.gov/books/NBK539124/"]Executive Summary - Clinical Review Report: Tesamorelin (Egrifta) - NCBI Bookshelf[/URL] Sami H. Tuffaha, Prateush Singh, Joshua D. Budihardjo, Kenneth R. Means, James P. Higgins, Jaimie T. Shores, Roberto Salvatori, Ahmet Höke, W.P. Andrew Lee & Gerald Brandacher (2016) Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury, Expert Opinion on Therapeutic Targets, 20:10, 1259-1265, DOI: 10.1080/14728222.2016.1188079 [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
Everything Tesamorelin
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top